Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitin...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 72; no. 7; pp. 1247 - 1250
Main Authors:	Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 08-04-2021
Subjects:	Antiviral Agents - therapeutic use Azetidines Brief Reports COVID-19 - drug therapy Humans Purines Pyrazoles Retrospective Studies SARS-CoV-2 Sulfonamides Treatment Outcome COVID-19 baricitinib hyper-inflammation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciaa879